1.miR-132 and miR-942 Expression Levels in Children with Attention Deficit and Hyperactivity Disorder: A Controlled Study
Seyma COSKUN ; Mehmet KARADAG ; Cem GOKCEN ; Serdar OZTUZCU
Clinical Psychopharmacology and Neuroscience 2021;19(2):262-268
Objective:
Although attention deficit hyperactivity disorder (ADHD) is a disease with high genetic transition, our knowledge about the mechanism of the disease is limited. In this study, it was aimed to evaluate the levels of miR-132-3p and miR-942-5p that are associated with the dopamine carrier protein gene (DAT1) and dopamine receptor 5 (DRD5) genes, which have been shown to play a role in the development of ADHD.
Methods:
According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition, 50 children diagnosed with ADHD and 48 healthy controls were included in the study. Affective Disorders and Schizophrenia Interview Schedule-Now and Lifetime Version-Turkish Adaptation was used to evaluate ADHD and the diagnoses accompanying ADHD. Quantitative Real-Time Polymerase Chain Reaction was used to evaluate miR-132-3p and miR-942-5p expression levels.
Results:
It was observed that miR-132-3p level (p = 0.001) was significantly higher with children with ADHD compared to the control group, and the level of miR-942-5p (p = 0.181) was higher in ADHD but did not reach statistically significant level.
Conclusion
In our study, we found that the increase in the miR-132-3p levels of children with ADHD may be a therapeutic target of the disease.
2.miR-132 and miR-942 Expression Levels in Children with Attention Deficit and Hyperactivity Disorder: A Controlled Study
Seyma COSKUN ; Mehmet KARADAG ; Cem GOKCEN ; Serdar OZTUZCU
Clinical Psychopharmacology and Neuroscience 2021;19(2):262-268
Objective:
Although attention deficit hyperactivity disorder (ADHD) is a disease with high genetic transition, our knowledge about the mechanism of the disease is limited. In this study, it was aimed to evaluate the levels of miR-132-3p and miR-942-5p that are associated with the dopamine carrier protein gene (DAT1) and dopamine receptor 5 (DRD5) genes, which have been shown to play a role in the development of ADHD.
Methods:
According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition, 50 children diagnosed with ADHD and 48 healthy controls were included in the study. Affective Disorders and Schizophrenia Interview Schedule-Now and Lifetime Version-Turkish Adaptation was used to evaluate ADHD and the diagnoses accompanying ADHD. Quantitative Real-Time Polymerase Chain Reaction was used to evaluate miR-132-3p and miR-942-5p expression levels.
Results:
It was observed that miR-132-3p level (p = 0.001) was significantly higher with children with ADHD compared to the control group, and the level of miR-942-5p (p = 0.181) was higher in ADHD but did not reach statistically significant level.
Conclusion
In our study, we found that the increase in the miR-132-3p levels of children with ADHD may be a therapeutic target of the disease.
3.Methylphenidate Induced Lip and Tongue Biting.
Cem GOKCEN ; Mehmet KARADAG ; Ihsan AKSOY
Clinical Psychopharmacology and Neuroscience 2018;16(2):218-220
Attention deficit hyperactivity disorder (ADHD) is a life-long neurodevelopmental disorder and treatment depends on pharmacotherapy because of its biological origin. Stimulant drugs are the most commonly used treatment for ADHD and they have various side effects. Herein, we report a case who bit off the tip of her tongue with Osmotic Release Oral System methylphenidate (OROS MPH) 36 mg/day, bit the tip of her lower lip with immediate release (IR) MPH 10 mg/day and lateral part of her tongue with IR MPH 20 mg/day. A diagnosis of epilepsy was unlikely because of the normal neurological examination and electroencephalography findings. This case was considered as an atypical side effect of MPH such as perseverative/compulsive behaviours and movement disorders. Clinicians should be aware of that stimulant medications may cause lip and tongue biting behavior and this may effect treatment compliance tremendously.
Attention Deficit Disorder with Hyperactivity
;
Compliance
;
Diagnosis
;
Drug Therapy
;
Electroencephalography
;
Epilepsy
;
Lip*
;
Methylphenidate*
;
Movement Disorders
;
Neurodevelopmental Disorders
;
Neurologic Examination
;
Stereotypic Movement Disorder
;
Tongue*
4.Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors.
Berna CAGATAY KAYA ; Hasan KARADAG ; Ozgur ONER ; Aysegul KART ; Mehmet Hakan TURKCAPAR
Psychiatry Investigation 2015;12(2):260-262
OBJECTIVE: Altered serum S100B protein levels have been shown in several psychiatric disorders. Our aim was to investigate whether plasma S100B is different in patients with panic disorder (PD) when compared with controls. Our second aim was to investigate whether treatment with SSRIs have an effect on S100B levels in patients with PD. METHODS: The sample included 32 patients diagnosed with PD (21 women, 11 men) per DSM-IV criteria and 21 healthy controls (11 women, 10 men). S100B levels were measured with BioVendor Human S100B ELISA (Enzyme Linked Immunosorbent Assay) kit. RESULTS: 14 patients were not on drug treatment (43.8%) while 18 patients were taking various SSRIs. Median S100B value was 151.7 pg/mL (minimum-maximum: 120.4-164.7 pg/mL) in the control group, 147.4 pg/mL (minimum-maximum: 138.8-154.1 pg/mL) in the drug free group and 153.0 pg/mL (minimum-maximum: 137.9-164.7 pg/mL) in the treatment group. Kruskal-Wallis analysis showed a significant diffrerence among the three groups (z=9.9, df=2, p=0.007). Follow up Mann-Whitney-U tests indicated that while the control and the patients with treatment were not significantly different (z=-0.05, p=0.96), there were significant differences between the control group and untreated patients (z=-2.6, p=0.009) and treated and untreated patients (z=-3.0, p=0.003). CONCLUSION: Our results suggested that, serum S100B protein level might be decreased in untreated PD patients and that patients who were treated with SSRIs had similar S100B level to healthy controls.
Diagnostic and Statistical Manual of Mental Disorders
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Follow-Up Studies
;
Humans
;
Panic Disorder*
;
Plasma
;
Serotonin*
5.Long-Term Substance Use Can Cause Irreversible Photopic Vision Changes in Substance Use Disorder in Remission
Oguzhan Bekir EGILMEZ ; Mehmet Hamdi ORUM ; Ali KUSTEPE ; Ayse Sevgi KARADAG ; Aysun KALENDEROGLU
Psychiatry Investigation 2020;17(10):1037-1043
Objective:
Substance use has such effects on pupil diameter. Although there is knowledge about the acute effects of substances on pupils, studies showing their chronic effects are limited. The aim of the present study was to evaluate the effect of long-term substance use on scotopic, mesopic, and photopic vision.
Methods:
The present study with cross-sectional desgn was conducted at the Adiyaman Training and Research Hospital for Psychiatry in Adiyaman. This study involved 110 substance use disorder (SUD) patients and 46 healthy volunteers as the control. The parameters were measured and recorded automatically by a device.
Results:
The mean age was 23.44±5.53 years in the SUD group and 24.26±5.38 years in healthy controls (p=0.420). The mean age of onset of the substance was 17.74±3.89 years and the mean duration of substance use was 3.54±2.9 years. It was determined that the patients had not used any substance for a mean of 121.73±117.49 days. There was no significant difference between patient and control groups in terms of scotopic and mesopic measurements of both eyes (p>0.05). Photopic measurements were significantly higher in the patient group than in the control group (p<0.05). Photopic measurements were significantly higher in the opioid, cannabis, ecstasy, and multiple substance use groups than in the control group (p<0.05).
Conclusion
The most important topic of this study is that photopic vision is permanently impaired in patients with a history of chronic substance use. This was attributed to disrupted sympathetic-parasympathetic hierarchy.
6.Alveolar echinococcosis localized in the liver, lung and brain.
Seyit Mehmet KAYACAN ; Sezai VATANSEVER ; Suleyman TEMIZ ; Bora USLU ; Dilek KAYACAN ; Vakur AKKAYA ; Osman ERK ; Bülent SAKA ; Aytac KARADAG ; Kultigin TURKMEN ; Fatih YAKAR ; Kerim GULER
Chinese Medical Journal 2008;121(1):90-92
Aged
;
Brain
;
parasitology
;
Echinococcosis, Hepatic
;
diagnosis
;
etiology
;
therapy
;
Echinococcosis, Pulmonary
;
diagnosis
;
etiology
;
therapy
;
Female
;
Humans
;
Lymphoma, T-Cell
;
complications